SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,756,920 | -29.6% | 121,000 | +1.4% | 0.00% | -50.0% |
| Q2 2023 | $2,496,949 | +2.2% | 119,300 | +3.1% | 0.00% | 0.0% |
| Q1 2023 | $2,443,584 | -25.8% | 115,700 | -10.6% | 0.00% | 0.0% |
| Q4 2022 | $3,293,230 | +20.9% | 129,400 | +14.2% | 0.00% | 0.0% |
| Q3 2022 | $2,723,000 | +34.5% | 113,300 | +7.7% | 0.00% | +100.0% |
| Q2 2022 | $2,024,000 | +24.7% | 105,200 | +12.6% | 0.00% | 0.0% |
| Q1 2022 | $1,623,000 | -13.1% | 93,400 | +9.5% | 0.00% | 0.0% |
| Q4 2021 | $1,867,000 | +14.5% | 85,300 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,630,000 | +14.2% | 85,300 | +2.6% | 0.00% | 0.0% |
| Q2 2021 | $1,427,000 | -13.9% | 83,100 | +12.1% | 0.00% | 0.0% |
| Q1 2021 | $1,657,000 | +1.8% | 74,100 | +1.2% | 0.00% | 0.0% |
| Q4 2020 | $1,628,000 | – | 73,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |